T-lymphocyte maturation-associated protein gene as a candidate metastasis suppressor for head and neck squamous cell carcinomas

Cancer Science

Volumn 100, Issue 5, 2009, Pages 873-880

  Beder, Levent Bekir ^a   Gunduz, Mehmet ^a,b   Hotomi, Muneki ^a   Fujihara, Keiji ^a   Shimada, Jun ^a   Tamura, Shinji ^a   Gunduz, Esra ^b   Fukushima, Kunihiro ^b   Yaykasli, Kursat ^b   Grenman, Reidar ^c   Shimizu, Kenji ^b   Yamanaka, Noboru ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; T LYMPHOCYTE MATURATION ASSOCIATED PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HEAD AND NECK CANCER; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; METASTASIS INHIBITION; METHYLATION; MICROSATELLITE MARKER; NECK METASTASIS; PRIORITY JOURNAL; PROMOTER REGION; SQUAMOUS CELL CARCINOMA; SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; AZACITIDINE; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HETEROZYGOTE; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MUTATION; MYELIN PROTEINS; NEOPLASM METASTASIS; PROTEOLIPIDS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 65349187054     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01132.x     Document Type: Article

References (25)

1. Tannapfel A, Weber A. Tumor markers in squamous cell carcinoma of the head and neck: Clinical effectiveness and prognostic value. Eur Arch Otorhinolaryngol 2001; 258: 83-8.
2. Mamelle G, Pampurik J, Luboinski B, Lancar R, Lusinchi A, Bosq J. Lymph node prognostic factors in head and neck squamous cell carcinomas. Am J Surg 1994; 168: 494-8.
3. Rinker-Schaeffer CW, O'Keefe JP, Welch DR, Theodorescu D. Metastasis suppressor proteins: Discovery, molecular mechanisms, and clinical application. Clin Cancer Res 2006; 12: 3882-9.
4. Schmalbach CE, Chepeha DB, Giordano TJ et al. Molecular profiling and the identification of genes associated with metastatic oral cavity/ pharynx squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004; 130: 295-302.
5. Belbin TJ, Singh B, Smith RV et al. Molecular profiling of tumor progression in head and neck cancer. Arch Otolaryngol Head Neck Surg 2005; 131: 10-18.
6. Sok JC, Kuriakose MA, Mahajan VB, Pearlman AN, DeLacure MD, Chen FA. Tissue-specific gene expression of head and neck squamous cell carcinoma in vivo by complementary DNA microarray analysis. Arch Otolaryngol Head Neck Surg 2003; 129: 760-70.
7. Kornberg LJ, Villaret D, Popp M et al. Gene expression profiling in squamous cell carcinoma of the oral cavity shows abnormalities in several signaling pathways. Laryngoscope 2005; 115: 690-8.
8. Rancano C, Rubio T, Correas I, Alonso MA. Genomic structure and subcellular localization of MAL, a human T-cell-specific proteolipid protein. J Biol Chem 1994; 269: 8159-64.
9. Alonso MA, Millan J. The role of lipid rafts in signalling and membrane trafficking in T lymphocytes. J Cell Sci 2001; 114: 3957-65.
10. Liebert M, Hubbel A, Chung M et al. Expression of mal is associated with urothelial differentiation in.vitro: Identification by differential display reverse-transcriptase polymerase chain reaction. Differentiation 1997; 61: 177-85.
11. Cheong KH, Zacchetti D, Schneeberger EE, Simons K. VIP17/MAL, a lipid raft-associated protein, is involved in apical transport in MDCK cells. Proc Natl Acad Sci USA 1999; 96: 6241-8.
12. Gunduz M, Beder LB, Gunduz E et al. Downregulation of ING3 mRNA expression predicts poor prognosis in head and neck cancer. Cancer Sci 2008; 99: 531-8.
13. Tracey L, Villuendas R, Ortiz P et al. Identification of genes involved in resistance to interferon-α in cutaneous T-cell lymphoma. Am J Pathol 2002; 161: 1825-37.
14. Beder LB, Gunduz M, Ouchida M et al. Identification of a candidate tumor suppressor gene RHOBTB1 located at a novel allelic loss region 10q21 in head and neck cancer. J Cancer Res Clin Oncol 2006; 132: 19-27.
15. Mimori K, Shiraishi T, Mashino K et al. MAL gene expression in esophageal cancer suppresses motility, invasion and tumorigenicity and enhances apoptosis through the Fas pathway. Oncogene 2003; 22: 3463-71.
16. Marazuela M, Acevedo A, Adrados M, Garcia-Lopez MA, Alonso MA. Expression of MAL, an integral protein component of the machinery for raft-mediated pical transport, in human epithelia. J Histochem Cytochem 2003; 51: 665-74.
17. Puertollano R, Alonso MA. Targeting of MAL, a putative element of the apical sorting machinery, to glycolipid-enriched membranes requires a pre-golgi sorting event. Biochem Biophys Res Commun 1999; 254: 689-92.
18. Fish EM, Molitoris BA. Alterations in epithelial polarity and the pathogenesis of disease states. N Engl J Med 1994; 330: 1580-8.
19. Ransom DT, Barnett TC, Bot J et al. Loss of heterozygosity on chromosome 2q: Possibly a poor prognostic factor in head and neck cancer. Head Neck 1998; 20: 404-10.
20. Yamamoto N, Mizoe J, Numasawa H, Tsujii H, Shibahara T, Noma H. Allelic loss on chromosomes 2q, 3p and 21q: Possibly a poor prognostic factor in oral squamous cell carcinoma. Oral Oncol 2003; 39: 796-805.
21. Otsuka T, Kohno T, Mori M, Noguchi M, Hirohashi S, Yokota J. Deletion mapping of chromosome 2 in human lung carcinoma. Genes Chromosomes Cancer 1996; 16: 113-19.
22. Yamamoto N, Mizoe JE, Numasawa H et al. Allelic loss of chromosome 2 in human oral squamous cell carcinoma: Correlation with lymph node metastasis. Oral Oncol 2003; 39: 64-8.
23. Hatta M, Nagai H, Okino K et al. Down-regulation of members of glycolipid-enriched membrane raft gene family, MAL and BENE, in cervical squamous cell cancers. J Obstet Gynaecol Res 2004; 30: 53-8.
24. Lind GE, Ahlquist T, Kolberg M et al. Hypermethylated MAL gene -a silent marker of early colon tumorigenesis. J Transl Med 2008; 6: 13.
25. Kang Y, Siegel PM, Shu W et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3: 537-49.